Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Intravenous immunoglobulin [IVIg], plasma exchange [PE], and corticosteroids are efficacious treatment in chronic inflammatory demyelinating polyneuropathy [CIDP]. IVIg is effective in multifocal motor neuropathy [MMN]. NIS, NIS-weakness, sum scores of raw amplitudes of motor fiber (CMAPs) amplitudes, and Dyck/Rankin score provided reliable measures to detect and scale abnormality and reflect change; they are therefore ideal for office management of response-based immunotherapy (R-IRx) of CIDP. Using efficacious R-IRx, a large early and late therapeutic response (≥ one-fourth were in remission or had recovered) was demonstrated in CIDP. In MMN only an early improvement with late non-significant worsening was observed. The difference in immunotherapy response supports a fundamental difference between CIDP (immune attack on Schwann cells and myelin) and MMN (attack on nodes of Ranvier and axons).

Original languageEnglish (US)
Pages (from-to)488-497
Number of pages10
JournalMuscle and Nerve
Volume52
Issue number4
DOIs
StatePublished - Oct 1 2015

Keywords

  • CIDP
  • Immune therapy
  • MMN
  • Neurophysiologic tests
  • Signs

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy'. Together they form a unique fingerprint.

Cite this